Quest Diagnostics Incorporated (NYSE:DGX) — Market Cap & Net Worth
Market Cap & Net Worth: Quest Diagnostics Incorporated (DGX)
Quest Diagnostics Incorporated (NYSE:DGX) has a market capitalization of $25.91 Billion ($25.91 Billion) as of September 23, 2026. Listed on the NYSE stock exchange, this USA-based company holds position #1038 globally and #434 in its home market, demonstrating a -1.32% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Quest Diagnostics Incorporated's stock price $234.76 by its total outstanding shares 110373360 (110.37 Million). Also see DGX total asset value for a full breakdown of the balance sheet.
Quest Diagnostics Incorporated Market Cap History: 2015 to 2026
Quest Diagnostics Incorporated's market capitalization history from 2015 to 2026. Data shows growth from $6.51 Billion to $25.91 Billion (14.29% CAGR). Also see cash efficiency ratio of Quest Diagnostics Incorporated for how efficiently the company converts equity into cash flow.
Index Memberships
Quest Diagnostics Incorporated is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
S&P 500 Index
GSPC
|
$63.30 Trillion | 0.04% | #310 of 503 |
Weight: Quest Diagnostics Incorporated's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Quest Diagnostics Incorporated Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Quest Diagnostics Incorporated's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check today's stock price for Quest Diagnostics Incorporated for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
1.74x
Quest Diagnostics Incorporated's market cap is 1.74 times its annual revenue
Latest Price to Earnings (P/E) Ratio
19.31x
Quest Diagnostics Incorporated's market cap is 19.31 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $8.59 Billion | $7.51 Billion | $645.00 Million | 1.14x | 13.32x |
| 2017 | $9.38 Billion | $7.71 Billion | $772.00 Million | 1.22x | 12.15x |
| 2018 | $8.08 Billion | $7.53 Billion | $736.00 Million | 1.07x | 10.98x |
| 2019 | $10.60 Billion | $7.73 Billion | $858.00 Million | 1.37x | 12.35x |
| 2020 | $12.09 Billion | $9.44 Billion | $1.43 Billion | 1.28x | 8.45x |
| 2021 | $17.88 Billion | $10.79 Billion | $2.00 Billion | 1.66x | 8.96x |
| 2022 | $16.56 Billion | $9.88 Billion | $946.00 Million | 1.68x | 17.51x |
| 2023 | $14.90 Billion | $9.25 Billion | $854.00 Million | 1.61x | 17.44x |
| 2024 | $16.65 Billion | $9.87 Billion | $871.00 Million | 1.69x | 19.12x |
| 2025 | $19.15 Billion | $11.04 Billion | $992.00 Million | 1.74x | 19.31x |
Competitor Companies of DGX by Market Capitalization
Companies near Quest Diagnostics Incorporated in the global market cap rankings as of September 23, 2026. Review DGX tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Quest Diagnostics Incorporated by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #89 globally with a market cap of $224.59 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #155 globally with a market cap of $156.17 Billion USD.
- WuXi AppTec Co Ltd (SHG:603259): Ranked #456 globally with a market cap of $60.75 Billion USD ( CN¥415.14 Billion CNY).
- Natera Inc (NASDAQ:NTRA): Ranked #581 globally with a market cap of $47.01 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #89 | Thermo Fisher Scientific Inc | NYSE:TMO | $224.59 Billion | $658.52 |
| #155 | Danaher Corporation | NYSE:DHR | $156.17 Billion | $221.09 |
| #456 | WuXi AppTec Co Ltd | SHG:603259 | $60.75 Billion | CN¥167.85 |
| #581 | Natera Inc | NASDAQ:NTRA | $47.01 Billion | $390.90 |
Quest Diagnostics Incorporated Historical Marketcap From 2015 to 2026
Between 2015 and today, Quest Diagnostics Incorporated's market cap moved from $6.51 Billion to $ 25.91 Billion, with a yearly change of 14.29%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $25.91 Billion | +35.28% |
| 2025 | $19.15 Billion | +15.03% |
| 2024 | $16.65 Billion | +11.77% |
| 2023 | $14.90 Billion | -10.05% |
| 2022 | $16.56 Billion | -7.35% |
| 2021 | $17.88 Billion | +47.86% |
| 2020 | $12.09 Billion | +14.11% |
| 2019 | $10.60 Billion | +31.13% |
| 2018 | $8.08 Billion | -13.84% |
| 2017 | $9.38 Billion | +9.16% |
| 2016 | $8.59 Billion | +31.90% |
| 2015 | $6.51 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 23rd, 2026 the market cap of Quest Diagnostics Incorporated was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $25.91 Billion USD |
| MoneyControl | $25.91 Billion USD |
| MarketWatch | $25.91 Billion USD |
| marketcap.company | $25.91 Billion USD |
| Reuters | $25.91 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Quest Diagnostics Incorporated
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagn… Read more